Epoetin alfa--focus on dialyzability. Case study of the anemic patient.

Epoetin alfa therapy has typically been administered at the end of dialysis. A recently completed in vivo study with a small patient population strengthens previous study findings and suggests that this protein can be safely administered during high-flux dialysis without fear of membrane adsorption. Data indicate that successful use of this technique depends on a variety of factors, including the site of administration. If confirmed, these findings could benefit both patients and clinicians.